The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Most people are deficient in vitamin D3. You can supplement with 2000, 5000, or 10,000 IU of vitamin D3 but that may not be enough. The only way to tell if your blood has an adequate amount of D3 is to have a blood test for D3 and have your doctor examine the results.
As sleaze oozes from the Pentagon, banished Marine and Naval Academy alum Susanna Marcasi finds a web of corruption and must take on a man to whom all are beholden, Defense Secretary Manfred Stahl. Can she bring down the cloistered power brokers deep within the military’s superstructure and survive? Blood Stripe: The Susanna Marcasi Chronicles Find out more at – http://www.GinaMariaDiNicolo.com
There is a lot of controversy and debate about whether you need to do a colon cleansing. Some say it is necessary and others say it's a waste of money and can do your body harm. You can imagine who it says it harms. Doctors say it's a waste of time and practitioners that offer a colon cleansing service cleansing say it is not. So who will you believe?
During the Academy of Nutrition and Dietetics 2017 Food & Nutrition Conference & Expo™ in Chicago, scientists reported on a recent study which uncovered that the intake of pistachios reduces the rise in blood sugar and insulin in women diagnosed with gestational diabetes mellitus (GDM)—commonly known as gestational diabetes. The study, “Effects of Pistachio Intake on Postprandial Blood Glucose Response in Pregnant Women,” found when women who were gestational glucose intolerant (GIGT) or who were diagnosed with GDM ate pistachios, they had a significantly lower rise in blood glucose levels compared to eating whole wheat bread that was matched for calories.
To view the multimedia release go to:
https://www.multivu.com/players/English/8162751-american-pistachio-growers-pistachio-health-benefits-women-gestational-diabetes/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
